No Data
Is Shandong Jincheng Pharmaceutical Group (SZSE:300233) Using Too Much Debt?
Shandong Jincheng Pharmaceutical Group (300233.SZ) released its first quarter performance, with a net income of 35.0548 million yuan, a decline of 57.75%.
Shandong Jincheng Pharmaceutical Group (300233.SZ) released its first-quarter report for 2025, with revenue of 7.22...
Jincheng Pharmaceutical: Report for the first quarter of 2025
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Suzhi has been re-certified as a high-tech enterprise.
On April 21, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd. (referred to as "Jincheng Suzhi"), recently received the "High-tech Enterprise Certificate" issued jointly by the Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Taxation Bureau of the State Administration of Taxation. Issued date: December 26, 2024, Certificate number: GR202431002776, valid for three years.
Shandong Jincheng Pharmaceutical Group (300233.SZ): A notification of approval for the supplementary application of injectable cefotaxime sodium has been received.
On April 14, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its holding subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., recently received the "Supplementary Application Approval Notice" for injectable cefotaxime sodium issued by the National Medical Products Administration. Cefotaxime sodium is a third-generation cephalosporin antibiotic characterized by high efficiency, broad spectrum, low toxicity, and enzyme resistance. It has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, aerobic bacteria, and certain anaerobic bacteria, particularly demonstrating a stronger bactericidal effect against Gram-negative bacteria, making it suitable for pneumonia and other lower respiratory tract infections and urinary tract infections caused by sensitive bacteria.
Shandong Jincheng Pharmaceutical Group (300233.SZ): The revenue from the company's synthetic biology products such as glutathione and S-adenosylmethionine directly exported to the USA accounts for about 2%.
On April 8, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the company's revenue from directly exporting synthetic biology products such as glutathione and SAM (S-adenosylmethionine) to the USA accounts for about 2%. According to the list of products exempt from Global tariffs and reciprocal tariffs released by the White House, and after preliminary communication with certain customers in the USA, the company's food-grade glutathione, SAM, and PQQ are included in the exemption list. The company will continue to monitor changes in tariff policies and maintain communication with customers.
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
